BV02

Overview

BV02 is a 14-3-3 inhibitor and an antibacterial agent. BV02 enhances the cleavage of PARP and caspase-3 . BV02 induces Apoptosis , Autophagy , and enhances Akt activation. BV02 has anti- B. melitensis infection and epilepsy-promoting effects. BV02 can also be used in colitis research.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Bacterial Infection | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > PARP

Product Information

• Catalog No.: HY-101985
• CAS No.: 292870-53-2
• Molecular Formula: C20H15N3O5
• Molecular Weight: 377.36
• Purity: 99.75%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.25 mg/mL (3.31 mM); Clear solution
• Availability: In-stock

Source

Original product source